Genaissance Pharmaceuticals (GNSC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Genaissance Pharmaceuticals (GNSC)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jim Oravetz who wrote (7)	11/3/2000 10:41:19 PM
From: Jim Oravetz	Read Replies (1) of 183

Call Reply comments: Suggested to look for company recent S-1. CEO talked about: IPO raised $89M. Milestones promised to market, they delivered. Paper presented that indicted HAP technology has been validated. Patients 150 people working on problems. World largest capacity for DNA variation study. Owns 59 - ABI 3700 DNA analyzers, more to come. 1200 patents submitted, each a full gene, not SNP's Delivered new mngr: Dr. Kenneth Casten(sp?) now VP of research - experienced in many areas. CFO speaks: Kevin (.49) loss. Invested $7.8M in R&D. SGA - $2.2M $121M in the bank. CEO Will deliver HAP contract with large pharma next Q. Persuing patient filings for IP. Goal to exceed 3000 genes studied (index repository) in 100 diverse individuals. Jim

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next